自动化免疫印迹法检测丙型肝炎病毒IgG抗体的补充确认试验
该研究开发了一种基于自动化免疫印迹平台、使用第四代HCV重组融合蛋白的HCV-WES检测方法,用于确认抗-HCV筛查阳性结果。基于70份特征明确样本的测试显示,特异性为100%,敏感性为95%;在205份HCV RNA阴性/抗-HCV阳性样本中,HCV-WES与INNO-LIA的阳性符合率分别为72.7%和71.2%。
要点
- HCV-WES是一种自动化免疫印迹法,用于确认抗-HCV筛查阳性结果。
- 在70份特征明确样本中,HCV-WES特异性100%、敏感性95%。
- 在205份HCV RNA阴性/抗-HCV阳性样本中,HCV-WES阳性率72.7%,INNO-LIA为71.2%。
核心结论
- HCV-WES自动化免疫印迹法可作为抗-HCV筛查阳性结果的补充确认试验,具有概念验证性。
研究设计与样本
- 研究开发了基于自动化免疫印迹平台、使用第四代HCV重组融合蛋白的HCV-WES检测方法。
- 基于70份特征明确样本评估性能,其中40份HCV RNA和抗-HCV阳性、15份HCV RNA阳性/抗-HCV阴性、15份HCV RNA和抗-HCV阴性。
- 通过测试205份HCV RNA阴性/抗-HCV阳性样本,比较HCV-WES与INNO-LIA的一致性。
主要发现
- 在70份特征明确样本中,HCV-WES特异性为100%,敏感性为95%。
- 在205份HCV RNA阴性/抗-HCV阳性样本中,149份(72.7%)经HCV-WES检测为阳性,146份(71.2%)经INNO-LIA检测为阳性。
关键数值与推荐
- HCV-WES在70份特征明确样本中的特异性为100%,敏感性为95%。
- 在205份HCV RNA阴性/抗-HCV阳性样本中,HCV-WES阳性率为72.7%(149/205),INNO-LIA阳性率为71.2%(146/205)。
临床怎么用
- HCV-WES可用于确认抗-HCV筛查阳性结果,尤其在无HCV RNA检测时具有监测价值。
- 相比手动Western blot和INNO-LIA,HCV-WES具有易用、成本较低和减少手工操作时间的优势。
局限性
- 研究为概念验证性,样本量有限(70份特征明确样本和205份一致性样本)。
- HCV-WES尚未获得FDA批准,INNO-LIA在欧洲可用但未获FDA批准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An estimated 41,200 people were newly infected with hepatitis C virus (HCV) in 2016 in the United States. Screening tests for antibodies to HCV may generate up to 32% false positivity in low-risk populations. Current Centers for Disease Control and Prevention (CDC) screening recommendations do not require confirmatory testing of a screening anti-HCV-positive test; however, confirmation is valuable for surveillance in the absence of HCV RNA testing. A recombinant immunoblot assay (RIBA) was used as a confirmatory assay for anti-HCV-reactive samples but was discontinued in 2013. Another anti-HCV confirmatory assay, INNO-LIA, is commercially available in Europe but is not approved by the Food and Drug Administration (FDA) in the United States. We report the development of an anti-HCV assay that was performed on an automated immunoblot platform using a fourth-generation HCV recombinant fusion protein. Based on testing of 70 well-characterized samples, of which 40 were HCV RNA and anti-HCV positive, 15 were HCV RNA positive/anti-HCV negative, and 15 were HCV RNA and anti-HCV negative, the specificity and sensitivity of the HCV-WES assay were 100% and 95%, respectively. Concordance between INNO-LIA and HCV-WES was determined by testing 205 HCV RNA-negative/anti-HCV-positive samples, of which 149 (72.7%) were positive by HCV-WES, while 146 (71.2%) were positive by INNO-LIA. We have shown proof of concept for the use of this test for confirmation of screened anti-HCV results. The HCV-WES assay has advantages over manual Western blot assays and INNO-LIA, including ease of use, lower cost, and reduced hands-on time.
引用
- Kodani M, Martin M, de Castro VL, et al. An Automated Immunoblot Method for Detection of IgG Antibodies to Hepatitis C Virus: a Potential Supplemental Antibody Confirmatory Assay. J Clin Microbiol. 2019. PMID: 30651390. doi:10.1128/JCM.01567-18
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。